Bli medlem
Bli medlem

Du är här

2016-10-21

Ogeda SA: Euroscreen announces name change to Ogeda and completion of Series B financing

Euroscreen announces name change to Ogeda and completion of Series B financing

New identity reflects Ogeda's successful transition to GPCR drug
discovery&development

October 19, 2016, 7 a.m. CET - Euroscreen today became Ogeda. The new
corporate identity, as Ogeda, reflects the Company's primary focus on the
discovery and development of first-in-class small molecule drug candidates
targeting G-Protein Coupled Receptors (GPCRs). Ogeda also launched a new
corporate website that is accessible on: www.ogeda.com

The launch of its new corporate brand follows the successful completion of the
second and final tranche of the Company's EUR 18 million Series B financing,
which was first announced in October 2015. The second tranche of funding was
subject to the completion of clinical milestones with lead product ESN364,
which is currently in three parallel Phase IIa trials for Menopausal Hot
Flashes, PolyCystic Ovary Syndrome (PCOS) and Uterine Fibroids. All
milestones were achieved ahead of schedule and the additional funds will be
used to fully finance the ongoing clinical programs.

Jean Combalbert, CEO of Ogeda, said: "Our new identity reflects our ambition
to continue to explore new frontiers
in the discovery and development of medicines based on our long-established
expertise in GPCRs. With the successful completion of the Series B funding
round and our lead clinical trial program for ESN364 on track, we look
forward to continued progress in inventing and developing innovative
treatments in areas of significant unmet need."

Ogeda's services unit Euroscreen Fast, offering an integrated services
solution for GPCR R&D projects, will continue to operate under its current
name as a business unit of Ogeda.

About Ogeda

Ogeda is a Belgium-based, privately owned Drug Discovery Company developing
first-in-class small molecule drug candidates targeting G-Protein Coupled
Receptors (GPCRs). The Company's orally-available and highly specific lead
product ESN364 is currently in Phase II clinical development for the
treatment of Women's Health Disorders. Ogeda has additional small molecules
targeting GPCRs in preclinical development in multiple therapeutic areas
including CNS, endocrinology and inflammation. Ogeda is backed by leading
investors, including Vesalius Biocapital, Fund+ and SRIW. For more
information, please visit: www.ogeda.com

About ESN364

ESN364 is a proprietary, oral, small-molecule, discovered and developed by
Ogeda for the purpose of the treatment of Women's Health Disorders. ESN364 is
superior to the existing, marketed GnRH ligands as it reduces levels of the
ovarian hormones estrogen and progesterone in a non-castrating manner as
required for the safe, effective treatment of UF and Endometriosis. In
addition, its selective action on gonadotropins uniquely positions ESN364 for
the treatment of PCOS. Furthermore, its mechanism of action to mimic the
neuronal effects of estrogen to control body temperature supports the use of
ESN364 to directly and safely address the basis for Hot Flashes in menopausal
women.

--------------------------------------------------------------------------------------------
| Contacts |
| Ruth Devenyns Jean Combalbert |
| Chief Financial Officer Chief Executive Officer |
|+32 71 348 500 +32 71 348 520 |
| info@ogeda.com info@ogeda.com |
| |
| Consilium Strategic Communications |
| Chris Gardner, Jonathan Birt, Hendrik Thys and Melissa Gardiner |
|+44 20 3709 5700 |
| ogeda@consilium-comms.com |
--------------------------------------------------------------------------------------------

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ogeda SA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.